Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Authors:
- Jean A. HurteauJHJean A. Hurteau
- Mark F. BradyMBMark F. Brady
- Kathleen M. DarcyKDKathleen M. Darcy
- William P. McGuireWMWilliam P. McGuire
- Pamela EdmondsPEPamela Edmonds
- Michael L. PearlMPMichael L. Pearl
- Iouri IvanovIIIouri Ivanov
- Krishnansu S. TewariKTKrishnansu S. Tewari
- Robert S. MannelRMRobert S. Mannel
- Kristine ZanottiKZKristine Zanotti
- Doris M. BenbrookDoris M. Benbrook
Open Access
- 1 December 2010
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 119 (3) , 444-450
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)Journal of Clinical Oncology, 2009
- A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancerGynecologic Oncology, 2008
- Estrogen Receptor β: An Overview and UpdateNuclear Receptor Signaling, 2008
- Vascular Endothelial Growth Factor Is a Target Gene for Estrogen Receptor and Contributes to Breast Cancer Progression2008
- Integration of the Extranuclear and Nuclear Actions of EstrogenMolecular Endocrinology, 2005
- Estrogen Signaling: A Subtle Balance Between ER and ERMolecular Interventions, 2003
- Serum tumor marker CA 125 for monitoring ovarian cancer during follow-upScandinavian Journal of Clinical and Laboratory Investigation, 2002
- Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart DiseaseJNCI: Journal of the National Cancer Institute, 2001
- Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary ReportGynecologic Oncology, 1996
- Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second-line therapy in 105 patientsCancer, 1991